A Study of CTX-712 in Relapsed/Refractory Acute Myeloid Leukemia and Higher Risk Myelodysplastic Syndromes

NCT05732103 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

RECRUITING

Status

225

Enrollment

INDUSTRY

Sponsor class

Conditions

Acute Myeloid Leukemia
Myelodysplastic Syndromes

Interventions

DRUG: CTX-712

Sponsor

Chordia Therapeutics, Inc.

Collaborators

[object Object]